ASPERCREME LIDOCAINE FOOT (DIABETIC)- lidocaine hydrochloride cream 
Chattem, Inc.

Disclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they comply with applicable regulations and policies. FDA has not evaluated whether this product complies.

----------

Aspercreme Lidocaine Foot Cream-Diabetic

ASPERCREME with LIDOCAINE FOOT PAIN CREAM

(For Diabetic Skin)

Drug Facts

Active ingredient

Purpose

Lidocaine HCl 4%............................................................................................................................Topical anesthetic

Use

temporarily relieves minor pain

Warnings

For external use only 

Do not use

■ if you have serious foot problems, such as ulcers or infections 

■ if you have numbness or reduced ability to feel pain

■ on cut, irritated or swollen skin

■on puncture wounds

■ for more than one week without consulting a doctor

When using this product

■ use only as directed. Read and follow all directions and warning on this carton.

■ do not allow contact with the eyes and the mucous membranes

■ do not bandage tightly or apply local heat (such as heating pads) or a medicated patch to the area of use

■ do not use at the same time as other topical analgesics

Stop use and ask a doctor if

■ condition worsens 

■ redness is present

■ irritation develops

■ symptoms persist for more than 7 days or clear up and occur again within a few days

If pregnant or breast-feeding,

ask a health professional before use.

Keep out of reach of children.

If swallowed, get medical help or contact a Poison Control Center right away.

Directions

adults and children over 12 years:

■ apply a thin layer to affected area every 6 to 8 hours, not to exceed 3 applications in a 24 hour period

■ massage into painful area until thoroughly absorbed into skin

        

children 12 years or younger: ask a doctor

Inactive ingredients

water, alcohol denat. (10%), cetearyl alcohol, ceteth-20 phosphate, dimethicone, caprylyl methicone, dicetyl phosphate, glyceryl stearate, aloe barbadensis leaf juice, panthenol, tocopheryl acetate, magnesium ascorbyl phosphate, aminomethyl propanol, C30-45 alkyl cetearyl dimethicone crosspolymer, acrylates/C10-30 alkyl acrylate crosspolymer, ethylhexylglycerin, methylparaben, disodium EDTA, citric acid

                                                                                   333-105

Child-resistant packaging. Close cap tightly after use.

PRINCIPAL DISPLAY PANEL

Max Strength
Aspercreme
Lidocaine
2 in 1
Pain Relief + Moisturization
foot cream

PRINCIPAL DISPLAY PANEL Max Strength Aspercreme Lidocaine 2 in 1 Pain Relief + Moisturization foot cream

ASPERCREME LIDOCAINE FOOT (DIABETIC) 
lidocaine hydrochloride cream
Product Information
Product TypeHUMAN OTC DRUGItem Code (Source)NDC:41167-0597
Route of AdministrationTOPICAL
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
LIDOCAINE HYDROCHLORIDE (UNII: V13007Z41A) (LIDOCAINE - UNII:98PI200987) LIDOCAINE HYDROCHLORIDE ANHYDROUS4 g  in 100 g
Inactive Ingredients
Ingredient NameStrength
WATER (UNII: 059QF0KO0R)  
ALCOHOL (UNII: 3K9958V90M)  
CETOSTEARYL ALCOHOL (UNII: 2DMT128M1S)  
CETETH-20 PHOSPHATE (UNII: 921FTA1500)  
DIMETHICONE (UNII: 92RU3N3Y1O)  
CAPRYLYL TRISILOXANE (UNII: Q95M2P1KJL)  
DIHEXADECYL PHOSPHATE (UNII: 2V6E5WN99N)  
GLYCERYL MONOSTEARATE (UNII: 230OU9XXE4)  
ALOE VERA LEAF (UNII: ZY81Z83H0X)  
PANTHENOL (UNII: WV9CM0O67Z)  
.ALPHA.-TOCOPHEROL ACETATE (UNII: 9E8X80D2L0)  
MAGNESIUM ASCORBYL PHOSPHATE (UNII: 0R822556M5)  
AMINOMETHYLPROPANOL (UNII: LU49E6626Q)  
C30-45 ALKYL CETEARYL DIMETHICONE CROSSPOLYMER (UNII: 4ZK9VP326R)  
ETHYLHEXYLGLYCERIN (UNII: 147D247K3P)  
METHYLPARABEN (UNII: A2I8C7HI9T)  
EDETATE DISODIUM ANHYDROUS (UNII: 8NLQ36F6MM)  
CITRIC ACID MONOHYDRATE (UNII: 2968PHW8QP)  
CARBOMER INTERPOLYMER TYPE A (ALLYL SUCROSE CROSSLINKED) (UNII: 59TL3WG5CO)  
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:41167-0597-01 in 1 CARTON06/01/2018
1113 g in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
OTC monograph not finalpart34806/01/2018
Labeler - Chattem, Inc. (003336013)

Revised: 5/2022
Document Id: 2a7bd4bf-e8fa-4b02-8fb8-1eb578a5929b
Set id: 2c33d15e-5032-46d9-bd98-5abc7df3bbe5
Version: 1
Effective Time: 20220506
 
Chattem, Inc.